Northern Trust Corp Sells 17,202 Shares of Integra LifeSciences Holdings Corporation $IART

Northern Trust Corp cut its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 1.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 875,223 shares of the life sciences company’s stock after selling 17,202 shares during the quarter. Northern Trust Corp owned about 1.13% of Integra LifeSciences worth $19,246,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. CWM LLC lifted its position in Integra LifeSciences by 413.8% in the first quarter. CWM LLC now owns 6,664 shares of the life sciences company’s stock worth $147,000 after buying an additional 5,367 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in Integra LifeSciences in the first quarter worth $223,000. NorthRock Partners LLC bought a new stake in Integra LifeSciences in the fourth quarter worth $251,000. Wealth Enhancement Advisory Services LLC bought a new stake in Integra LifeSciences in the first quarter worth $251,000. Finally, Natixis Advisors LLC bought a new stake in Integra LifeSciences in the first quarter worth $297,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Performance

IART stock opened at $15.13 on Tuesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The business has a 50-day moving average price of $13.12 and a 200 day moving average price of $15.90. The company has a market capitalization of $1.18 billion, a P/E ratio of -2.32, a PEG ratio of 0.85 and a beta of 1.20. Integra LifeSciences Holdings Corporation has a 1-year low of $11.06 and a 1-year high of $27.13.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The firm had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm’s quarterly revenue was down .6% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the topic of a number of recent analyst reports. Wells Fargo & Company reduced their target price on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their target price on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 6th. Finally, JMP Securities reduced their target price on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $18.43.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.